Talazoparib Dosage
Medically reviewed by Drugs.com. Last updated on Oct 17, 2023.
Applies to the following strengths: 0.1 mg; 0.25 mg; 0.35 mg; 0.5 mg; 0.75 mg; 1 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Breast Cancer
1 mg orally once a day until disease progression or unacceptable toxicity
Comments:
- Select patients based on the presence of germline BRCA mutations as determined by an FDA-approved test.
Use: For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer
Renal Dose Adjustments
Mild renal impairment: No adjustment recommended
Moderate renal impairment (CrCl 30 to 59 mL/min): 0.75 mg orally once a day
Severe renal impairment (CrCl 15 to 29 mL/min): 0.5 mg orally once a day
Liver Dose Adjustments
No adjustment recommended
Dose Adjustments
DOSE REDUCTIONS FOR ADVERSE REACTIONS:
- Recommended starting dose: 1 mg orally once daily
- First dose reduction: 0.75 mg orally once a day
- Second dose reduction: 0.5 mg orally once a day
- Third dose reduction: 0.25 mg orally once a day
DOSE MODIFICATIONS:
- Hemoglobin less than 8 g/dL: Withhold therapy until levels resolve to 9 g/dL or greater; resume therapy at a reduced dose.
- Platelet count less than 50,000/microliters: Withhold therapy until levels resolve to 75,000 microliters or greater; resume therapy at a reduced dose.
- Neutrophil count less than 1000/microliters: Withhold therapy until levels resolve to 1500 microliters or greater; resume therapy at a reduced dose.
- Nonhematologic Grade 3 or 4: Withhold therapy until levels resolve to Grade 1 or less; Consider resuming therapy at a reduced dose or discontinue therapy.
DOSE MODIFICATIONS FOR USE WITH P-GLYCOPROTEIN (P-GP) INHIBITORS:
- Reduce the dose to 0.75 mg once daily when coadministered with certain P-gp inhibitors.
- When the P-gp inhibitor is discontinued, increase the dose (after 3 to 5 half-lives of the P-gp inhibitor) to the dose used prior to the initiation of the P-gp inhibitor.
Precautions
CONTRAINDICATIONS:
- None
This drug is not recommended for use in children.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- This drug may be taken with or without food.
- The capsules should be swallowed whole and not opened or dissolved.
- If the patient vomits or misses a dose, an additional dose should not be taken; take the next prescribed dose at the usual time.
Storage requirements:
- Store at 20C to 25C (68F to 77F); excursions permitted between 15C to 30C (59F to 86F).
Monitoring:
- Monitor complete blood counts monthly.
Patient advice:
- Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
- Patients should contact their healthcare provider if they experience weakness, feeling tired, fever, weight loss, frequent infections, bruising, bleeding easily, breathlessness, blood in urine or stool, and/or laboratory findings of low blood cell counts, or a need for blood transfusions.
- Females should inform their healthcare provider if they are pregnant or become pregnant.
- Inform female patients of the risk to a fetus and potential loss of the pregnancy.
Frequently asked questions
More about talazoparib
- Check interactions
- Compare alternatives
- Side effects
- During pregnancy
- Drug class: PARP inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.